Healthcare diagnostics company Quest Diagnostics (NYSE: DGX) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 9.2% year on year to $2.90 billion. The company’s full-year revenue guidance of $11.84 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $2.50 per share was 5.6% above analysts’ consensus estimates.
Is now the time to buy DGX? Find out in our full research report (it’s free for active Edge members).
Quest (DGX) Q1 CY2026 Highlights:
- Revenue: $2.90 billion vs analyst estimates of $2.82 billion (9.2% year-on-year growth, 2.7% beat)
- Adjusted EPS: $2.50 vs analyst estimates of $2.37 (5.6% beat)
- Adjusted EBITDA: $594 million vs analyst estimates of $537.8 million (20.5% margin, 10.5% beat)
- The company slightly lifted its revenue guidance for the full year to $11.84 billion at the midpoint from $11.76 billion
- Management raised its full-year Adjusted EPS guidance to $10.73 at the midpoint, a 1.2% increase
- Operating Margin: 13.8%, in line with the same quarter last year
- Sales Volumes rose 10.9% year on year (12.4% in the same quarter last year)
- Market Capitalization: $22.69 billion
StockStory’s Take
Quest Diagnostics delivered first quarter results that exceeded Wall Street’s revenue and profit expectations, driven by broad-based demand for its clinical innovations and expansion into new areas like end-stage renal disease and brain health. Management attributed the organic growth to increased test volumes across physician, hospital, and consumer channels, alongside productivity gains from automation and artificial intelligence. CEO James Davis highlighted the strong adoption of advanced diagnostics, particularly in Alzheimer’s testing, noting, “Our Alzheimer’s book of testing more than doubled year-over-year.”
Looking ahead, Quest Diagnostics’ updated guidance reflects optimism around the continued strength of organic volume growth, new partnerships with health systems, and the scaling of advanced diagnostics. Management sees sustained contributions from collaborations with organizations like Fresenius Medical Care and Corewell Health, as well as new product introductions in cardiometabolic and autoimmune testing. CFO Sam Samad emphasized, “We expect strong utilization and revenue per requisition, excluding the impact of large partnerships, to continue driving results throughout the year.”
Key Insights from Management’s Remarks
Management identified strong demand for advanced diagnostics, new health system partnerships, and consumer-driven testing as key drivers of the quarter’s growth, while ongoing automation efforts supported margin stability.
-
Advanced diagnostics traction: Double-digit revenue growth continued in areas like Alzheimer’s and cardiometabolic testing, supported by new clinical guidelines recommending broader cholesterol screening and novel biomarkers. Quest’s AD-Detect blood test was specifically noted for its growing adoption by both primary care and specialist physicians.
-
Health system collaborations expand: Partnerships with Fresenius Medical Care and Corewell Health drove significant increases in test volumes, with Corewell’s collaboration helping Quest achieve double-digit growth in the hospital channel. Implementation of the Corewell joint venture, including a new lab in Michigan, remains on track for next year.
-
Consumer testing momentum: The direct-to-consumer business, questhealth.com, and collaborations with leading wearable and wellness brands posted strong double-digit growth. Repeat customer rates were high, and new test offerings such as Elite health profile and hormone panels resonated with consumers seeking proactive health management.
-
AI and automation productivity gains: Ongoing deployment of artificial intelligence and automation technologies improved efficiency, including a 40% productivity boost among customer service agents and the launch of the Quest AI Companion to help patients interpret lab results.
-
Operational excellence through Invigorate: The Invigorate program continued to deliver targeted annual cost savings and productivity improvements, offsetting wage inflation and external headwinds like fuel costs. This focus on operational discipline contributed to stable margins despite increased investment in growth initiatives.
Drivers of Future Performance
Quest expects continued organic growth, deeper health system integration, and advanced diagnostics to be the main themes shaping its outlook.
-
Ongoing health system partnerships: Management anticipates sustained test volume growth from Fresenius Medical Care and Corewell Health collaborations, each contributing materially to the revenue base. As these partnerships mature, margin profiles are expected to improve, particularly in the second half of the year as ramp-up costs diminish.
-
Expansion of advanced diagnostics: Continued investment in areas like brain health, oncology, and cardiometabolic testing is expected to drive higher revenue per requisition. Management cited expanding clinical adoption and additional research collaborations as factors that should support growth in high-value testing segments.
-
Consumer and digital health growth: The direct-to-consumer and value-added reseller channels, bolstered by new wellness and wearable partnerships, are forecasted to maintain strong momentum. Management noted the solid margin profile of these channels, as cash-pay tests reduce denial risk and administrative overhead, supporting overall profitability.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be watching (1) the continued ramp-up and margin improvement in health system partnerships with Corewell and Fresenius, (2) the pace of advanced diagnostic test adoption, especially in Alzheimer’s and cardiometabolic categories, and (3) ongoing growth in consumer testing channels and digital partnerships. Execution on Project Nova and regulatory developments around Medicare pricing are also critical signposts.
Quest currently trades at $207.52, up from $196.31 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
